Cytomx Therapeutics Inc Financials
This page shows Cytomx Therapeutics Inc (CTMX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Cytomx Therapeutics Inc has an operating margin of 18.1%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 90/100, reflecting efficient cost management and pricing power. This is up from -6.4% the prior year.
Cytomx Therapeutics Inc's revenue surged 36.4% year-over-year to $138.1M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Cytomx Therapeutics Inc's current ratio of 1.25 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.
While Cytomx Therapeutics Inc generated -$86.2M in operating cash flow, capex of $310K consumed most of it, leaving -$86.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Cytomx Therapeutics Inc scores -1.39, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($926.8M) relative to total liabilities ($121.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Cytomx Therapeutics Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cytomx Therapeutics Inc generates $-2.71 in operating cash flow (-$86.2M OCF vs $31.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Cytomx Therapeutics Inc generated $138.1M in revenue in fiscal year 2024. This represents an increase of 36.4% from the prior year.
Cytomx Therapeutics Inc's EBITDA was $26.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 716.4% from the prior year.
Cytomx Therapeutics Inc generated -$86.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 52.2% from the prior year.
Cytomx Therapeutics Inc reported $31.9M in net income in fiscal year 2024. This represents an increase of 5700.9% from the prior year.
Cytomx Therapeutics Inc earned $0.38 per diluted share (EPS) in fiscal year 2024. This represents an increase of 3900.0% from the prior year.
Cytomx Therapeutics Inc held $38.1M in cash against $0 in long-term debt as of fiscal year 2024.
Cytomx Therapeutics Inc had 80M shares outstanding in fiscal year 2024. This represents an increase of 19.0% from the prior year.
Cytomx Therapeutics Inc's operating margin was 18.1% in fiscal year 2024, reflecting core business profitability. This is up 24.5 percentage points from the prior year.
Cytomx Therapeutics Inc's net profit margin was 23.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 23.6 percentage points from the prior year.
Cytomx Therapeutics Inc invested $83.4M in research and development in fiscal year 2024. This represents an increase of 7.3% from the prior year.
Cytomx Therapeutics Inc invested $310K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 63.1% from the prior year.
CTMX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0M-68.0% | $18.7M-63.4% | $50.9M+33.7% | $38.1M+51.7% | $25.1M-39.4% | $41.5M+55.8% | $26.6M+0.8% | $26.4M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $15.3M+14.9% | $13.3M-29.4% | $18.9M+27.6% | $14.8M-41.2% | $25.2M+14.1% | $22.1M+13.8% | $19.4M+17.9% | $16.4M |
| SG&A Expenses | $6.4M-2.9% | $6.6M-29.8% | $9.4M+67.6% | $5.6M-33.0% | $8.4M+8.3% | $7.8M-0.9% | $7.8M+14.9% | $6.8M |
| Operating Income | -$15.8M-1126.1% | -$1.3M-105.7% | $22.6M+28.0% | $17.7M+309.2% | -$8.5M-172.5% | $11.7M+2023.6% | -$606K-119.4% | $3.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $58K-7.9% | $63K+1.6% | $62K-1.6% | $63K+23.5% | $51K+4.1% | $49K-95.4% | $1.1M-62.1% | $2.8M |
| Net Income | -$14.2M-9139.6% | -$154K-100.7% | $23.5M+24.6% | $18.9M+388.9% | -$6.5M-147.4% | $13.8M+1547.7% | $837K-72.0% | $3.0M |
| EPS (Diluted) | $-0.09 | $0.00-100.0% | $0.27+22.7% | $0.22+375.0% | $-0.08-147.1% | $0.17+750.0% | $0.02-50.0% | $0.04 |
CTMX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $158.3M-9.6% | $175.1M+77.7% | $98.5M-18.3% | $120.5M-24.3% | $159.2M-13.8% | $184.7M-8.5% | $201.8M-8.8% | $221.2M |
| Current Assets | $149.2M-9.4% | $164.6M+90.0% | $86.6M-19.3% | $107.3M-25.0% | $143.1M-14.4% | $167.2M-8.6% | $182.9M-9.1% | $201.2M |
| Cash & Equivalents | $34.2M-30.3% | $49.0M+3.0% | $47.6M+25.1% | $38.1M-12.0% | $43.2M+19.5% | $36.2M+110.7% | $17.2M-34.0% | $26.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.6M-12.8% | $1.9M-4.4% | $2.0M-37.0% | $3.1M+11.8% | $2.8M-78.9% | $13.2M+283.9% | $3.4M+41.9% | $2.4M |
| Goodwill | $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | $949K |
| Total Liabilities | $50.9M-7.8% | $55.1M-24.9% | $73.4M-39.3% | $121.0M-36.5% | $190.4M-12.0% | $216.4M-13.2% | $249.2M-8.5% | $272.4M |
| Current Liabilities | $41.0M+4.6% | $39.2M-21.9% | $50.2M-41.5% | $85.8M-40.0% | $142.9M-1.2% | $144.5M-7.3% | $155.9M+6.2% | $146.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $107.4M-10.4% | $119.9M+378.7% | $25.0M+5593.2% | -$456K+98.5% | -$31.2M+1.4% | -$31.7M+33.2% | -$47.4M+7.4% | -$51.2M |
| Retained Earnings | -$682.4M-2.1% | -$668.2M0.0% | -$668.1M+3.4% | -$691.6M+3.4% | -$716.2M-0.9% | -$709.7M+1.9% | -$723.4M+0.1% | -$724.3M |
CTMX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.5M+1.3% | -$15.8M+25.1% | -$21.0M-5.7% | -$19.9M-1.8% | -$19.5M+24.9% | -$26.0M-18.6% | -$22.0M-20.4% | -$18.2M |
| Capital Expenditures | -$127K-570.4% | $27K-77.3% | $119K+48.8% | $80K-16.7% | $96K-16.5% | $115K-56.8% | $266K+2855.6% | $9K |
| Free Cash Flow | -$15.7M+0.7% | -$15.8M+25.4% | -$21.2M-5.9% | -$20.0M-1.7% | -$19.6M+24.9% | -$26.2M-17.7% | -$22.2M-21.8% | -$18.3M |
| Investing Cash Flow | $439K+100.6% | -$76.4M-349.6% | $30.6M+102.2% | $15.1M-29.6% | $21.5M-52.1% | $44.9M+248.9% | $12.9M+130.0% | -$42.9M |
| Financing Cash Flow | $253K-99.7% | $93.5M | $0-100.0% | $2.2M-55.9% | $5.1M+2830.5% | $174K-28.7% | $244K-99.2% | $29.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CTMX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -264.4%-257.5pp | -6.9%-51.3pp | 44.4%-2.0pp | 46.4%+80.1pp | -33.7%-61.8pp | 28.1%+30.4pp | -2.3%-14.1pp | 11.8% |
| Net Margin | -238.6%-237.8pp | -0.8%-47.0pp | 46.2%-3.3pp | 49.5%+75.6pp | -26.0%-59.3pp | 33.3%+30.1pp | 3.1%-8.2pp | 11.3% |
| Return on Equity | N/A | N/A | 93.9% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.0%-8.9pp | -0.1%-24.0pp | 23.9%+8.2pp | 15.7%+19.8pp | -4.1%-11.6pp | 7.5%+7.1pp | 0.4%-0.9pp | 1.4% |
| Current Ratio | 3.64-0.6 | 4.20+2.5 | 1.73+0.5 | 1.25+0.2 | 1.00-0.2 | 1.16-0.0 | 1.17-0.2 | 1.37 |
| Debt-to-Equity | 0.47+0.0 | 0.46-2.5 | 2.93+268.3 | -265.33-259.2 | -6.10+0.7 | -6.83-1.6 | -5.25+0.1 | -5.32 |
| FCF Margin | -262.9%-178.3pp | -84.6%-43.0pp | -41.6%+10.9pp | -52.5%+25.7pp | -78.2%-15.1pp | -63.1%+20.5pp | -83.5%-14.4pp | -69.2% |
Note: Shareholder equity is negative (-$456K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Cytomx Therapeutics Inc's annual revenue?
Cytomx Therapeutics Inc (CTMX) reported $138.1M in total revenue for fiscal year 2024. This represents a 36.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cytomx Therapeutics Inc's revenue growing?
Cytomx Therapeutics Inc (CTMX) revenue grew by 36.4% year-over-year, from $101.2M to $138.1M in fiscal year 2024.
Is Cytomx Therapeutics Inc profitable?
Yes, Cytomx Therapeutics Inc (CTMX) reported a net income of $31.9M in fiscal year 2024, with a net profit margin of 23.1%.
What is Cytomx Therapeutics Inc's earnings per share (EPS)?
Cytomx Therapeutics Inc (CTMX) reported diluted earnings per share of $0.38 for fiscal year 2024. This represents a 3900.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Cytomx Therapeutics Inc's EBITDA?
Cytomx Therapeutics Inc (CTMX) had EBITDA of $26.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cytomx Therapeutics Inc's operating margin?
Cytomx Therapeutics Inc (CTMX) had an operating margin of 18.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Cytomx Therapeutics Inc's net profit margin?
Cytomx Therapeutics Inc (CTMX) had a net profit margin of 23.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Cytomx Therapeutics Inc's free cash flow?
Cytomx Therapeutics Inc (CTMX) generated -$86.5M in free cash flow during fiscal year 2024. This represents a -52.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cytomx Therapeutics Inc's operating cash flow?
Cytomx Therapeutics Inc (CTMX) generated -$86.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Cytomx Therapeutics Inc's total assets?
Cytomx Therapeutics Inc (CTMX) had $120.5M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cytomx Therapeutics Inc's capital expenditures?
Cytomx Therapeutics Inc (CTMX) invested $310K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Cytomx Therapeutics Inc spend on research and development?
Cytomx Therapeutics Inc (CTMX) invested $83.4M in research and development during fiscal year 2024.
How many shares does Cytomx Therapeutics Inc have outstanding?
Cytomx Therapeutics Inc (CTMX) had 80M shares outstanding as of fiscal year 2024.
What is Cytomx Therapeutics Inc's current ratio?
Cytomx Therapeutics Inc (CTMX) had a current ratio of 1.25 as of fiscal year 2024, which is considered adequate.
What is Cytomx Therapeutics Inc's debt-to-equity ratio?
Cytomx Therapeutics Inc (CTMX) had a debt-to-equity ratio of -265.33 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cytomx Therapeutics Inc's return on assets (ROA)?
Cytomx Therapeutics Inc (CTMX) had a return on assets of 26.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Cytomx Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Cytomx Therapeutics Inc (CTMX) had $38.1M in cash against an annual operating cash burn of $86.2M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Cytomx Therapeutics Inc's debt-to-equity ratio negative or unusual?
Cytomx Therapeutics Inc (CTMX) has negative shareholder equity of -$456K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cytomx Therapeutics Inc's Altman Z-Score?
Cytomx Therapeutics Inc (CTMX) has an Altman Z-Score of -1.39, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cytomx Therapeutics Inc's Piotroski F-Score?
Cytomx Therapeutics Inc (CTMX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cytomx Therapeutics Inc's earnings high quality?
Cytomx Therapeutics Inc (CTMX) has an earnings quality ratio of -2.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cytomx Therapeutics Inc?
Cytomx Therapeutics Inc (CTMX) scores 55 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.